Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS

NMR in Biomedicine

Volumn 19, Issue 6, 2006, Pages 655-668

  Mueller, S G ^a   Schuff, N ^a   Weiner, M W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diffusion tensor imaging; Functional magnetic resonance imaging; Magnetic resonance imaging; Neurodegeneration; Outcome measure; Spectroscopy; Treatment; Volumetry

Indexed keywords

ALZHEIMER'S DISEASE; DIFFUSION TENSOR IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; NEURODEGENERATION; NEURODEGENERATIVE DISEASES;

BIOMARKERS; BIOMEDICAL ENGINEERING; BRAIN; MAGNETIC RESONANCE IMAGING; METABOLISM; NEUROPHYSIOLOGY; PATHOLOGY;

NEUROLOGY;

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA SECRETASE INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINESTERASE INHIBITOR; CITICOLINE; DONEPEZIL; GAMMA SECRETASE INHIBITOR; LEVODOPA; NEUROPROTECTIVE AGENT; PLACEBO; PRAMIPEXOLE; PROPENTOFYLLINE; RIVASTIGMINE; ROPINIROLE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATAXIA; BLOOD OXYGENATION; BRAIN ATROPHY; BRAIN METABOLISM; CLINICAL TRIAL; COGNITION; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INTERMETHOD COMPARISON; LEWY BODY; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROIMAGING; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIOECONOMICS; TEST RETEST RELIABILITY; TREATMENT OUTCOME; VOLUMETRY;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DEMENTIA, VASCULAR; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 33749504441     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1062     Document Type: Review

References (111)

1. Przedborski S, Vial M, Jackson-Lewis V. Neurodegeneration: what is it and where are we? J. Clin. Invest. 2003; 111: 3-10.
2. Katzman R, Fox P. The world-wide impact of dementia. Projections of prevalence and costs. In Epidemiology of Alzheimer's Disease: from Gene to Prevention, Mayeaux R, Christen Y (eds). Springer-Verlag: Berlin, 1999; 1-17.
3. O'Hara R, Yesavage JA, Derouesne C. Therapeutic approaches to age-associated neurocognitive disorders. Dialogues in clinical neuroscience. Cerebral Aging Concepts Assess. 2001; 3: 191-213.
4. Mayeux R, Sano M. Treatment of Alzheimer's disease. N. Engl. J. Med. 1999; 341: 1670-1679.
5. Leber P. Slowing the progression of Alzheimer's disease: methodological issues. Alzheimer Dis. Assoc. Disord. 1997; 11 (Suppl 5): S10-S21.
6. Mani R. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory review. Stat. Med. 2004; 23: 305-314.
7. Hsu YY, Schuff N, Du AT, Mark K, Zhu X, Hardin D, Weiner MW. Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. J. Magn. Reson. Imaging 2002; 16: 305-310.
8. Jack CR, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58: 750-757
9. Bobinski M, De Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisnewski HM. The histological validation of post mortem magnetic resonance imaging determined hippocampal volume in Alzheimer's disease. Neuroscience 2000; 95: 721-725.
10. De Leon MJ, Desanti S, Zinkowski R, Metha PD, Pratico D, Segal S, Calk C, Kerkman D, Deberardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J. Intern. Med. 2004; 256: 205-223.
11. Resnick SM, Pham DL, Kraut MA, Zondrmann AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J. Neurosci. 2003; 23: 3295-3301.
12. Fox NC, Schrott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet 2004; 363: 392-394.
13. Gunter JL, Shiung MM, Manduca A, Jack CR. Methodological considerations for measuring rates of brain atrophy. J. Magn. Reson. Imaging 2003; 18: 16-24.
14. Chatelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping of gray matter loss with voxel based morphometry in mild cognitive impairment. Neuroreport 2002; 13: 1939-1943.
15. Cardenas VA, Du AT, Hardin D, Ezekiel F, Weber P, Jagust WJ, Chui HC, Schuff N, Weiner MW. Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia. Neurobiol. Aging 2003; 24: 537-544.
16. Freebourogh PA, Foc NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans. Med. Imag. 1997; 15: 623-629.
17. Karas GB, Burton EJ, Rombouts SA, van Schijndel RA, O'Brien JT, Scheltens P, McKeith IG, Williams D, Ballard C, Barkhof F. A comprehensive study of gray matter loss in patients with Alzheimer's disease using voxel based morphometry. Neuroimage 2003; 18: 895-907.
18. Studholme C, Cardenas V, Maudsley A, Weiner MW. An intensity consistent filtering approach to the analysis of deformation tenser derived maps of brain shape. Neuroimage 2003; 19: 1638-1649.
19. Kessler RM. Imaging methods for evaluating brain function in man. Neurobiol. Aging 2003; Suppl. 1: S21-S35.
20. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost effectivness of PET in the diagnosis of Alzheimer disease. Radiology 2003; 228: 515-522.
21. Frahm J, Krueger G, Merboldt KD, Kleinschmidt A. Dynamic NMR studies of perfusion and oxidative metabolism during focal brain activation. Adv. Exp. Med. Biol. 1997; 413: 195-203.
22. Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative phophorylation genes in patients with Alzheimer's disease: implication for early mitochondrial dysfunction and oxidative damage. Neuromol. Med. 2004; 5: 147-162.
23. Mc Gonigle DJ, Howseman AM, Athwal BS, Friston KJ, Frackowiak RS, Holmes AP. Variability in fMRI: an examination of intersession differences. Neuroimage 2000; 11: 708-734.
24. Small SA. High resolution MRI: a promising approach for diagnosing Alzheimer's disease and mapping its course. Alzheimer Dis. Assoc. Disord. 2003; 17: 154-161.
25. Baslow MH. N-Acetylaspartate in the vertebrate brain:metabolism and function. Neurochem. Res. 2003; 28: 941-953.
26. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acteylaspartate in Alzheimer's disease. Lancet 2000; 355: 1696-1697.
27. 1H NMR spectroscopy of individual human brain metabolites at moderate field strengths. Magn. Reson. Imaging 2003; 21: 1295-1302.
28. Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JC, Jones B, Lyketsos C, Dulberg C. Incidence and prevalence of dementia in the Cardiovascular Health Study. J. Am. Geriatr. Soc. 2004; 52: 195-204.
29. McKeith I, Mintzer J, Aarsaland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Felman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lippa OL, Machado JC, O'Brien J, Playfer J, Reid W. Dementia with Lewy bodies. Lancet Neurol. 2004; 3: 19-28.
30. Hodges JR. Frontotemporal dementia (Pick's disease): clinical features and assessment. Neurology 2001: 56 (Suppl. 4): S6-S10.
31. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
32. Cummings JL. Alzheimer's disease. N. Engl. J. Med. 2004; 351: 56-67.
33. Hock C, Konietzko U, Streffer JR, Tracey J, Signorell A, Muller-Tilmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554.
34. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disase. Neurobiol. Aging 2004; 25 (Suppl. 2): 84.
35. Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. 1996; Suppl. 165: 3-12.
36. Delacourt A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-1165.
37. Petersen RC. Mild cognitive impairment a diagnostic entity. J. Intern. Med. 2004; 256: 183-194.
38. Jack CR, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E. Rates of hippcampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-489.
39. Xu Y, Jack CR, O'Brien PC, Kokmen E, Smith GE, Ivnik RJ, Boeve BF, Tangalos RG, Petersen RC. Usefullness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000; 54: 1760-1767.
40. Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, Yaffe K, Kramer JH, Reed B, Norman D, Chui HC, Weiner MW. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2001; 71: 441-447.
41. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer's disease and normal ageing for clinical trials. Arch. Neurol. 2004; 61: 59-66.
42. De Toledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, Wuu J, Turner DA. MRI derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol. Aging 2004; 9: 1197-1203.
43. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 2001; 58: 1985-1999.
44. Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, Semple J, Hong MS, Herman DH, Gravano D, Doddrell DM, Toga AW. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 2004; 22: 1754-1766.
45. Wang L, Swank JS, Glick IE, Gado HM, Miller MI, Morris JC, Csernansky JG. Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage 2003; 20: 667-682.
46. Chan D, Janssen JC, Withwell JL, Watts HC, Jenkins R, Frost C, Rossor MN, Fox NC. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 2003; 362: 1121-1122.
47. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, Sexton G, Kaye JA. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003; 61: 487-492.
48. Killiany RJ, Gomez-Isla T, Moss M, Kikins R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol. 2000; 47: 430-439.
49. Bradley KM, Bydder GM, Budge MM, Hajnal JV, White SJ, Ripley BD, Smith AD. Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br. J. Radiol. 2002; 75: 506-513.
50. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer's disease. Power calculations and estimates of sample size to detect treatment effects. Arch. Neurol. 2000; 57: 339-344.
51. Jack CR, Shiung MM, Gunter JL, O'brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591-600.
52. Jack CR, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D, Petersen RC. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60: 253-260.
53. Krishnan KRR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am. J. Psychiatry 2003; 160: 2003-2011.
54. Rombouts SARB, Barkhof F, van Meel CS, Scheltens P. Alteration in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2002; 73: 665-671.
55. Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, Santulli RB. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127: 1574-1583.
56. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T. Measurement of acetylcholinesterase by positron emisson tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997; 349: 1805-1809.
57. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999; 52: 691-699.
58. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disase: a positron emission tomography study. Ann. Neurol. 2000; 48: 194-200.
59. Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T, Tanada S, Irie T. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001; 56: 408-410.
60. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol. 2000; 48: 391-395.
61. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes K, Gemmell HG, Murray AD. Cerebral blood flow and cognitive response to riivastigmine treatment in Alzheimer's disease. Neuroreport 2002; 13: 83-87.
62. Rodriguez G, Vitali P, Canfora M, Calvini P, Girtler N, De Leo C, Piccardo A, Nobili F. Quantitative EE and perfusional single photon emission computed tomography in Alzheimer's disease. Clin. Neurophysiol. 2004; 115: 39-49.
63. Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW. Neuropsychiatry Neuropsychol. Behav. Neurol. 2001; 14: 63-68.
64. Nobili F, Vitali P, Confora M, Girtler N, De Leo C, Mariani G, Pupi A, Rodriquez G. Effects of long term donepezil therapy on rCBF of Alzheimer's patients. Clin. Neurophysiol. 2002; 113: 1241-1248.
65. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J. Nucl. Med. 2001; 42: 1441-1445.
66. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, Pupi A, Robert PH, Rodriguez G, Darcourt J. Brain perfusion follow-up in Alzheimer's patients during treatment with acetyl-cholinesterase inhibitors. J. Nucl. Med. 2002; 43: 983-990.
67. Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J Neuropsychopharmacol. 2001; 3: 223-230.
68. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am. J. Geriatr. Psychiatry 2003; 11: 169-177.
69. Klunk WE;Engler H, Nordberg A, Wang Y, Blomquist G, Holt D, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Anotoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
70. Jellinger KA. The pathology of ischemic-vascular dementia: an update. J. Neurol. Sci. 2002; 203-204: 153-157.
71. Van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, Hofman PA, Karas G, Kjartansson O, De Leeuw FE, Prins ND, Schmidt R, Visser MC, Weinstein HC, Brakhof F. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003; 34: 1907-1912.
72. Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004; 35: 1010-1017.
73. O'Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, Gholkar A, Crum WR, Rossor MN, Fox NC. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD and vascular dementia. Neurology 2001; 56: 1386-1388.
74. Mungas D, Jagust WJ, Reed BR, Kramer JH, Weiner MW, Schuff N, Norman D, Mack WJ, Willis L, Chui H. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology 2001; 57: 2229-2235.
75. Mungas D, Reed BR, Jagust WJ, De Carli C, Mack WJ, Kramer JH, Weiner MW, Schuff N, Chui HC. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology 2002: 59: 867-873.
76. Cohen RA, Paul RH, Ott BR, Moser DJ, Zawacki TM, Stone W, Gordon N. The relationship of subcortical MRI hyperintensities and brain volume to cognitive function in vascular dementia. J. Int. Neuropsychol. Soc. 2002; 8: 743-752.
77. Boyle PA, Paul R, Moser D, Zawacki T, Gordon N, Cohen R. Cognitive neurologic predictors of functional impairment in vascular dementia. Am. J. Geriatr. Psychiatry 2003; 11: 103-106.
78. Pantoni L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J. Neurosci. 2004; 226: 67-70.
79. Broderick JP, Gaskill M, Dhawan A, Khoury JC. Temoral changes in brain volume and cognition in a randomized treatment trial of vascular dementia. J. Neuroimaging 2001; 11: 6-12.
80. Sweet LH, Paul RH, Cohen RA, Moser D, Ott BR, Gordon N, Browndyke JN, Shah P, Garrett KD. Neuroimaging correlates of dementia rating scale performance at baseline and 12 month follow up. Geriatr. Psychiatry Neurol. 2003; 16: 240-244.
81. Mielke R, Moller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B. Propentophylline in treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis. Assoc. Disord. 1998; 12 (Suppl. 2): S29-S35.
82. Lojkowska W, Ryglewicz D, Jedrzejczak T, Mine S, Jakubowska T, Jarosz H, Bochnyska A. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J. Neurol. Sci. 2003; 216: 119-126.
83. Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meiniger V, Miller RG, Mitsumoto H, Shaw P, Tashiro K, Van Den Berg L. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2004; 5: 84-98.
84. Kalra S, Arnold D. Neuroimaging in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003; 4: 243-248.
85. Karitzky J, Ludolph AC. Imaging and neurochemical markers for diagnosis and disease progression in ALS. J. Neurol. Sci. 2001; 191: 35-41.
86. Cheung G, Gawel MJ, Cooper PW, Farb RI, Ang LC, Gawel MJ. Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. Radiology 1995; 194: 263-270.
87. Ishikawa T, Nagura H, Yokota T, Yamanouchi H. Signal loss in the motor cortex on magnetic resonance images in amyotrophic lateral sclerosis. Ann. Neurol. 1993; 33: 218-222.
88. Waragai M. MRI and clinical features in amyotrophic lateral sclerosis. Neuroradiology 1997; 39: 847-851.
89. Graham JM, Papadakis N, Evans J, Widjaja E, Romanowski J, Paley MNJ, Wallis LI, Wilkinson ID, Shaw PJ, Griffiths PD. Diffusion tensor imaging for the assessment of upper motor neuron integrity in ALS. Neurology 2004; 63: 2111-2119.
90. Sach M, Winkler G, Glauche V, Liepert J, Heimbach B, Koch MA, Büchel C, Weiller C. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004; 127: 340-350.
91. Ellis CM, Suckling J, Amaro E, Bullmore ET, Simmons A, Williams SCR, Leigh PN. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001; 57: 1571-1578.
92. Peretti-Viton P, Azulay JP, Trefouret S, Brunel H, Daniel C, Viton JM, Flori A, Salazard B, Pouget J, Serratrice G, Salamon G. MRI of the intracranial corticospinal tracts in amyotrophic and primary lateral sclerosis. Neuroradiology 1999; 41: 744-749.
93. Rooney WD, Miller GR, Gelinas D, Schuff N, Maudsley AA, Weiner MW. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 1998; 50: 1800-1805.
94. 1H MRSI in amyotrophic lateral sclerosis. Magn. Reson. Med. 2001; 45: 513-516.
95. 1H magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001; 43: 189-197.
96. Kaufmann P, Pullman SL, Shungu DC, Chan S, Hays AP, Del Bene ML, Dover MA, Vukic M, Rowland LP, Mitsumoto H. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004; 62: 1753-1757.
97. Bowen BC, Pattany PM, Bradley WG, Murdoch JB, Rotta F, Younis AA, Duncan RC, Quencer RM. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. Am. J. Neuroradiol. 2000; 21: 647-658.
98. 1H MRSI. Neurology 2002; 58: 773-779.
99. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9: 1757-1761.
100. Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003; 4: 22-26.
101. Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. Am. J. Neuroradiol. 2003; 24: 476-480.
102. Sami A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 29: 1783-1793.
103. Schapira AHV. Disease modification in Parkinson's disease. Lancet Neurol. 2004; 3: 362-368.
104. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emisson tomography and magnetic resonance imaging in Parkinson's disease. Eur. J. Neurol. 2004; 11: 5-12.
105. Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. Am. J. Neuroradiol. 2000; 21: 697-701.
106. Yoshikawa K, Nakata Y, Yamata K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J. Neurol. Neurosurg. Psychiatry 2004; 75: 481-484.
107. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rasol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET study group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 2003; 54: 93-101.
108. The Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa in Parkinson disease progression. JAMA 2002; 287: 1653-1661.
109. The Parkinson Study Group. Does levodopa slow or hasten the rat eof progression of Parkinson's disease? The results of the ELL-DOPA trial. Neurology 2003; Suppl. 1: A80-A81.
110. Brooks DJ. Neuroimaging in Parkinson's disease. Neuro Rx 2004; 1: 243-254.
111. Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, Wengenack T. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability and in vivo targeting to Alzheimer's disase amyloid plaques. Biochemistry 2004; 43: 6064-6075.